励晶太平洋(00575.HK)旗下生物科技公司与Longenesis就管理整合及联邦学习方法发展合作
励晶太平洋(00575.HK)公布,其收购的生物科技公司Deep Longevity与Longenesis展开合作。Deep Longevity主营为可视化AI系统,该系统主要是跟踪人体分子、细胞、组织、器官、系统、生理和心理水平的衰老速度。此次合作方Longenesis则是领先的同意管理整合安全数据管理公司。
两家公司通过合作将Longenesis的数据安全系统整合到Deep Longevity开发的名为Young.AI的智能系统。系统是一个基於网络的老龄化和健康追踪器,以及一个联合学习框架的发展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.